Replies to post #62944 on Biotech Values

[DewDiligence]

>MNTA – Do you or know how strong Teva's patent position is around Copaxone (or is that a better question for ij)?<

In the US, Teva’s Copaxone patents that remain in force (until 2014) are on the formulation rather than the CoM. Although MNTA and NVS have not disclosed how they will circumvent these formulation patents, I think it’s reasonable to infer that this is a relatively easy task compared to characterization of the compound itself. The former presumably falls in NVS’ bailiwick while the latter is in MNTA’s.